

REVENIO

A stronger foundation for value creation

Participate in Revenio's rights offering September 28–October 12, 2026

This is not an official prospectus approved by the Finnish Financial Supervisory Authority under the Prospectus Regulation. The information presented in this marketing brochure is based on the prospectus published by Revenio Group Corporation, which is available at www.reveniogroup.fi/investors/rights_offering_2026. Investors are advised to carefully review the prospectus before making an investment decision.

Contents

General on the Offering.....3

From the CEO.....6

Revenio in brief7

Market.....9

Portfolio.....11

Go-to-market.....13

Strategy and value creation.....15

Key figures.....18

Questions and answers.....20

Risk factors22

Terms and conditions of the Offering24



General on the Offering

The Subscription Price is

EUR 6.19

per Offer Share

Revenio Group Corporation (“Revenio” or the “Company”) announced on April 13, 2026, in connection with the acquisition of LT International SAS, the parent company of Visionix International group, (the “Visionix Transaction”) that it was planning a rights offering. The Board of Directors of Revenio resolved on September 21, 2026, on a fully underwritten rights offering of approximately EUR 80 million (the “Offering”). The net proceeds received from the Offering will be used for the repayment of the outstanding EUR 80 million bridge-to-equity facility (the “Bridge Facility”) related to the Visionix Transaction, whereby Revenio aims to secure balanced capital structure and sufficient financial flexibility to execute its strategy.

In the Offering, the Company will offer for subscription, based on pre-emptive rights for existing shareholders, a maximum of 12,929,361 new shares in the Company (the “Offer Shares”)

based on the authorization granted by the Annual General Meeting of the Company held on May 12, 2026. The subscription price is EUR 6.19 per Offer Share (the “Subscription Price”).

The record date of the Offering is September 23, 2026 (the “Record Date”). Shareholders who are registered in Revenio’s shareholders’ register maintained by Euroclear Nordics Ltd on the Record Date will receive one (1) subscription right in the form of a book-entry (the “Subscription Right”) for each one (1) existing share of the Company owned by the shareholder on the Record Date. Nine (9) Subscription Rights entitle its holder to subscribe for four (4) Offer Shares at the Subscription Price.

Background of the Offering

The objective of the Offering is to fund a portion of the cash payments made by Revenio in connection with the Visionix Transaction by

repaying the outstanding Bridge Facility related to the Visionix Transaction, whereby Revenio aims to secure balanced capital structure and sufficient financial flexibility to execute its strategy. The Visionix Transaction is a key element in the execution of Revenio’s strategy and strengthens Revenio’s ability to accelerate growth and value creation through a broader market opportunity, increased scale and synergies arising from the Visionix Transaction.

To this end, the Company aims to raise gross proceeds of approximately EUR 80.0 million and net proceeds of approximately EUR 77.1 million by offering Offer Shares for subscription.

The Offering is fully underwritten, subject to customary terms and conditions

William Demant Invest A/S, Caravelle Capital SAS and the other sellers in the Visionix Transaction, have each separately and irrevocably committed to subscribe for on

the basis of the Subscription Rights allocated to them, an aggregate amount of approximately 31.4 percent of the Offer Shares offered in the Offering, and to pay the Subscription Price for such Offer Shares (either by itself and/or on behalf of its controlled entity) under certain customary conditions (each separately a “Subscription Commitment” and together, the “Subscription Commitments”).

In addition, Nordea Bank Abp (“Nordea”) has entered into an underwriting agreement with the Company (the “Underwriting Agreement”) pursuant to which Nordea has agreed, subject to certain customary terms and conditions, to procure subscribers for any Offer Shares that may remain unsubscribed for in the Offering, excluding the Offer Shares that are covered by the Subscription Commitments, or to subscribe for such Offer Shares itself.

Participation instructions

Options for action in the Offering:

1. You can use the Subscription Rights you have received to subscribe for Offer Shares in full.
2. You can purchase additional Subscription Rights or sell part of your Subscription Rights. You can also sell all of your Subscription Rights on the regulated market of Nasdaq Helsinki.
3. If you are not yet a shareholder of Revenio, you can purchase Subscription Rights from the regulated market of Nasdaq Helsinki and use them to subscribe for Offer Shares.
4. You can also make a secondary subscription without using Subscription Rights.

Remember to act in time:

Any unexercised Subscription Rights will expire without any compensation at the end of the subscription period on October 12, 2026, at 4:30 p.m. (Finnish time).

Your account operator, custodian or nominee may require that a sell or subscription order be submitted on a specific date prior to the end of trading in the Subscription Rights or the expiry of the subscription period.

To avoid losing the value of your Subscription Rights, you should either:

- Submit a subscription order to your investment service provider no later than on October 12, 2026, in accordance with the instructions provided by your investment service provider; or
- Sell your unused Subscription Rights no later than on October 6, 2026.

Example of a share subscription:

1. You own 90 shares in Revenio. You will receive 90 Subscription Rights that entitle you to subscribe for 40 Offer Shares at the Subscription Price.
2. You pay EUR 6.19 to subscribe for one new Offer Share, i.e. EUR 247.60 in total.
3. After the Offering, you own 130 shares in Revenio.

Important dates

September 23, 2026	Record Date of the Offering
September 28, 2026	Subscription period commences
on or about September 28, 2026	Trading in the Subscription Rights commences on the regulated market of Nasdaq Helsinki
September 29, 2026	Trading in the interim shares commences on the regulated market of Nasdaq Helsinki
October 6, 2026	Trading in the Subscription Rights ends on the regulated market of Nasdaq Helsinki
October 12, 2026	The subscription period of the Offering ends and unexercised Subscription Rights expire without any compensation
on or about October 13, 2026	Announcement of the preliminary results of the Offering
on or about October 15, 2026	Announcement of the final results of the Offering
on or about October 16, 2026	Trading in the interim shares ends on the regulated market of Nasdaq Helsinki
on or about October 16, 2026	The Offer Shares are registered in the trade register maintained by the Finnish Patent and Registration Office
on or about October 19, 2026	The Offer Shares subscribed for in the Offering will be recorded in the book-entry accounts of investors
on or about October 19, 2026	Trading in the Offer Shares commences on the regulated market maintained by Nasdaq Helsinki

From the CEO

The Visionix transaction marks a new phase for Revenio. We have joined two highly complementary companies and built a significantly broader platform to serve optical retail, optometry and ophthalmology across the clinical eye care customer journey. At the same time, we estimate that our total addressable market has expanded approximately 2.5-fold, from around USD 1.1 billion to approximately USD 2.7 billion, creating new opportunities for long-term growth.

A stronger foundation for growth and value creation

In our view, we are supported by the long-term growth drivers of the eye health market: population ageing and lifestyle-related diseases are increasing the need for eye disease screening and diagnostics faster than healthcare resources are growing. Eye care is, in our view, undergoing a transformation similar to that seen across healthcare more broadly: examinations, screening and diagnostics are increasingly being performed earlier and closer to the patient, enabling limited specialist care resources to be focused on those who need them most. As a result, eye health services are increasingly delivered outside traditional specialist care settings. In our view, this is driving demand

for solutions that enable reliable diagnostics, efficient workflows and use of data throughout the eye care pathway.

A larger market opportunity supported by structural growth

The new combined Revenio has been precisely built to address this significant market transformation. The key theme of our strategy for 2027–2029 is to lead the shift from vision care to connected eye health. With Visionix, we can combine a broader range of technologies and solutions related to screening and eye health diagnostics. Together, we have a more comprehensive offering, complementary capabilities and a broader global reach. Our value creation potential is based on our ambition to expand into new customer segments and markets, leverage shared sales channels, combine the strengths of our research and development activities, and improve operational efficiency. We have set a synergy target related to the acquisition that aims to improve EBITDA by more than EUR 20 million by the end of 2029 compared to the situation before the closing of the Visionix transaction, of which approximately EUR 5 million has already been secured.

Rights offering to support strategy execution

The rights offering provides our existing shareholders with an opportunity to participate in Revenio's next phase of development. The proceeds from the offering will be used to repay the bridge facility related to the Visionix acquisition, thereby supporting our objective of securing a balanced capital structure and sufficient financial flexibility to execute our strategy.

We enter this next phase from a position of strength. In our view, we operate in a structurally growing market, and our market potential is now significantly larger than before. Our broader offering, global reach and enhanced scale provide us with even stronger capabilities to respond to the evolving market, strengthen our position and capture the long-term growth opportunities we have identified in eye health.

Our objective is to deliver profitable growth and create sustainable shareholder value from our strengthened market position. I would like to thank you for your continued trust in Revenio.

Jouni Toijala
CEO



Revenio is one of the leading turnkey solutions providers in the global eye care market¹

Revenio offers efficient and easy to use tools for diagnosing and screening a wide variety of eye diseases.

Revenio's diagnostic devices include IOP measurement devices (tonometers), fundus imaging devices, perimeters and microperimeters under the iCare brand. By joining forces with Visionix in 2026, Revenio expanded its portfolio to include eye examination standard equipment, refraction systems, multimodal diagnostics, OCT and optical lab finishing equipment under well established brands, such as Visionix, Optovue, Briot and Weco.

The new broad portfolio is connected by Revenio's cloud-based platforms, enabling screening, remote solutions and leveraging AI, significantly broadening Revenio's ability to support the complete eye care workflow and patient journey. The combined portfolio covers the entire patient journey from refraction and screening to advanced diagnostics, helping eye care professionals deliver high-quality care more efficiently and across a broader range of care settings.

¹ Revenio's assessment based on historical growth and profitability



Key strengths

Revenio believes that the following factors constitute Revenio's key strengths:

01

The global eye care market is supported by powerful megatrends

02

A comprehensive offering to advance clinical confidence and workflow excellence

03

A scalable and efficient go-to-market model

04

Operational excellence and quality, with people and culture as the foundation

05

Well positioned for growth and value creation

The global eye care market is supported by powerful megatrends¹

01 | Ageing population

More people are developing age-related eye diseases, such as, cataracts, and glaucoma, requiring screening and treatment.

02 | Lifestyle related diseases

Increasing prevalence of, for example, diabetes, which is a source of several eye diseases, such as diabetic retinopathy, requiring screening and treatment.

03 | Labor shortage

Demand for eye care is outpacing the eye care workforce, forcing to do more with less, requiring delegation, automation and easy-to-use remote monitoring.

04 | Advancing technologies and treatment

Innovations in pharma and medical technology lead to new treatment opportunities, necessitating enhanced diagnostic tools and approaches.

05 | Expanding access to care

Increasing amount of care settings are adopting comprehensive health-focused eye exams, expanding addressable market for diagnostics. In Revenio's industry, more optical retailers grow their expertise in care.


¹ Revenio's assessment

A \$2.7 billion addressable market¹

The Visionix transaction increased Revenio’s total addressable market in diagnostic equipment by approximately 2.5 times from approximately USD 1.1 billion to approximately USD 2.7 billion.

Revenio estimates the total market to grow with a compound annual growth rate (CAGR) of 3.9 percent from 2025 to 2030, reaching approximately USD 5.0 billion in 2030.

The following chart sets forth information on the global ophthalmic diagnostic equipment market segments for the year ended December 31, 2025.



■ Pre-existing market segments for Revenio

■ New market segments for Revenio

¹ Revenio’s assessment

² Multimodal includes anterior scanners, ocular surface and wavefront diagnostics and corneal topographers.
Source: Revenio

Revenio’s key customer segments

Revenio’s key customer segments include optical retail, optometry and ophthalmology as well as other healthcare segments, such as pharma, universities and primary care.

Optical retail



The optical retail customer segment includes dispensing opticians and eye care opticians. The core tasks performed by the optical retail segment include efficient refraction, support for optical sales, eye health checks and referral workflows.

Optometry



The optometry customer segment includes retail and medical optometrists. The core tasks performed by the optometry segment include eye health screening and diagnosis, advanced analysis and progression data, and referral workflows.

Ophthalmology



The ophthalmology customer segment includes ophthalmology offices, generalists, sub-specialists and specialists. The core tasks performed by the ophthalmology segment include full scope eye diagnostics, treatments, long-term progress monitoring and surgical procedures.

A comprehensive offering to advance clinical confidence and workflow excellence



CLINICAL CUSTOMER JOURNEY

Standard equipment

Refraction systems

Tonometers

Multimodal devices


Fundus imaging

OCT

Perimetry & Microperimetry

ESSENTIAL DIAGNOSTICS

ADVANCED DIAGNOSTICS



CLOUD PLATFORM & TARGETED CUSTOMER-FACING SOLUTIONS

A significantly expanded direct footprint across the world’s largest markets

Revenio’s products are available through a combination of distributors, Revenio’s own sales network and OEM arrangements in more than 130 countries around the world. Revenio’s distribution strategy is designed to support scalability and facilitate expansion into international markets. Revenio sells products directly to end users in the United States, France, Italy, Spain, Germany, Belgium and Portugal, while in other regions it operates through a network of more than 400 distribution partners globally.

The following chart sets forth information on Revenio’s market presence, including each country’s proportional share of the total USD 4.1 billion market in 2025:



A scalable and efficient go-to-market model¹

The following are the priorities related to the value creation of Revenio's go-to-market model:

Capitalizing on the expanded commercial footprint:

Combining the best of both organizations to maximize broader market reach and commercial potential, strengthening competitiveness in key markets.

Leveraging scale and diversifying revenue streams:

Being more relevant across markets and customer segments as well as expanding revenue sources to maximize market impact and business resilience.

Increasing sales and margin contribution from direct channels:

Leveraging expanded direct access to customers to accelerate cross-selling and prospecting while insourcing incremental margins by selling direct.

Optimizing the distribution network:

Enhancing and optimizing indirect channels by market and segment, leveraging the combined network of over 400 distributors to accelerate growth and value creation for Revenio's customers.

¹ Revenio's assessment

Revenio’s strategy 2027–2029: Leading the shift from vision care to connected eye health

Based on the market development, Revenio’s updated strategy covering years from 2027 to 2029 focuses on leading the shift from vision care to connected eye health. By joining forces with Visionix in 2026, Revenio significantly broadened its offering and customer reach, particularly in vision care solutions for optical retail, complementing its established presence in diagnostic solutions for optometry and ophthalmology. Revenio’s combined portfolio covers the entire patient journey from refraction and screening to advanced diagnostics and aims to help eye care professionals to deliver high-quality care more efficiently and across a broader range of care settings. This provides, according to Revenio, a strong foundation for Revenio to reach more customers, offer more solutions and lead the shift toward connected eye health.



The strategy and its execution are based on four cornerstones:

Advancing Clinical Confidence and Workflow Excellence through connected product innovations and workflows that help customers deliver better eye care

Driving Commercial Excellence through customer-focused model

Scaling operational excellence with uncompromising quality

Developing People and Culture as a foundational strength

The updated strategy is a direct continuation of the previous strategy period covering years from 2024 to 2026, which focused on scaling the business towards connected and predictive eye care pathways. With the new strategic cornerstones and as one combined company

after joining forces with Visionix, Revenio is building on the complementary strengths and capabilities to continue sustainable and profitable growth.

Financial targets for the strategy period 2027–2029

The Board of Directors of the Company has adopted the following financial targets for the new strategy period, reflecting the strategic focus on sustainable and profitable growth:

- Organic net sales CAGR of 5 to 10 percent from 2027 to 2029.
- Adjusted EBITDA margin of 25 percent by the end of 2029.

Revenio's growth target is based on growing and cross-selling the combined portfolio, expanding customer reach and geographic access, and continuing the innovation and development of integrated solutions to support revenue generation.

The target to an adjusted EBITDA margin of 25 percent is based on the realization of the identified synergies of the Visionix transaction of more than EUR 20 million, operational leverage and scale benefits as well as increasing the share of targeted higher-margin services and software.

Organic Net Sales

5–10%

**CAGR target
2027–2029**

Adjusted EBITDA margin

25%

**by the end
of 2029**

Visionix integration and value creation plan

To support the integration and future development of the combined company, Revenio strengthened its Leadership Team following the Visionix Transaction. Integration efforts are overseen by the Leadership Team of Revenio and a dedicated integration team with clearly defined workstreams and accountabilities across both organizations, supported by selected external advisors and resources.

This integration is being executed in three phases:

2026–2027 Quick wins and mobilization:

Combining organizations, processes and system landscapes, realizing quick win synergies in, for example, procurement and go-to-market, and planning long term strategic synergies in, for example, assembly and new solutions.

2028–2029 Traction and build up:

Harvesting full cross sell synergies through a unified platform experience, continuing the development of new turnkey solutions combining leading technologies, and starting the optimization of assembly.

Beyond 2030 Continued growth and sustained leadership:

Extending market leadership through combined proprietary and distinct technologies, accelerating lead in the innovation agenda in eye care globally, and delivering unmatched business performance with best in class operations.

Revenio has set a target of more than EUR 20 million EBITDA uplift through joint value creation and synergies by the end of 2029 compared to the situation before the closing of the Visionix transaction.

Key figures

The following table sets forth Revenio’s key figures as at the dates and for the periods indicated:

	As at and for the six months ended June 30		As at and for the year ended December 31	
	2026	2025	2025	2024
	(unaudited)		(audited, unless otherwise indicated)	
(EUR in millions, unless otherwise indicated)				
Consolidated comprehensive profit & loss statement data				
Net sales	66.6	52.6	109.7	103.5
Operating profit	4.8	12.7	25.4	25.1
Operating profit %, percent	7.2	24.2	23.2 ¹	24.2 ¹
Profit for the period	3.0	7.3	17.4	18.5
Earnings per Share, EUR	0.112	0.273	0.655	0.695
Consolidated balance sheet data				
Assets total	479.2	135.2	150.6	141.3
Shareholders' equity total	149.5	104.4	114.7	107.7
Net debt	237.9	(1.3)	(15.3) ¹	(7.9) ¹
Consolidated cash flow statement data				
Net cash flow from operations	(5.8)	11.4	30.2	23.9
Net cash flow from investing activities	(168.6)	(1.5)	(5.2)	(8.8)
Net cash flow from financing activities	164.1	(13.5)	(16.6)	(16.1)

¹ Unaudited.

Unaudited Pro Forma Financial Information

The following table sets forth certain Unaudited Pro Forma Financial Information for the periods indicated:

	As at and for the six months ended June 30, 2026	For the year ended December 31, 2025
	(unaudited)	
(EUR in millions, unless otherwise indicated)		
Pro forma net sales	121.9	252.8
Pro forma EBITDA	16.2	35.7
Pro forma adjusted EBITDA	17.4	45.3
Pro forma operating profit	9.2	21.6
Pro forma operating profit %, percent	7.6	8.5
Pro forma profit for the period	7.1	3.2
Pro forma earnings per Share, EUR	0.169	0.076
Pro forma assets total	476.9	–
Pro forma shareholders' equity total	227.3	–
Pro forma net debt	160.8	–

The unaudited combined pro forma financial information (the “Unaudited Pro Forma Financial Information”) is presented for illustrative purposes only to give effect to the Visionix Transaction and related financing to Revenio’s historical financial information. The unaudited pro forma combined comprehensive profit & loss statements for the six months ended June 30, 2026, and for the year ended December 31, 2025, are presented as if the Visionix Transaction and related financing had been completed on January 1, 2025. As the Visionix Transaction has been included in Revenio’s unaudited consolidated balance sheet as at June 30, 2026, therefore only impacts of the subsequent Offering related to the Visionix Transaction have been adjusted in the pro forma balance sheet as if the subsequent Offering and its effects had taken place as at June 30, 2026.

The Unaudited Pro Forma Financial Information has been prepared by the management for illustrative purposes only and, because of its nature, it addresses a hypothetical situation, and therefore it is not necessarily indicative of the financial position or the results of operations that would have been actually realized had the Visionix Transaction and related financing completed as of the dates indicated, nor is it meant to be indicative of any anticipated financial position or future results of operations that will be experienced going forward. In addition, the accompanying unaudited pro forma combined income statement does not reflect any expected cost savings, synergy benefits or future integration costs that are expected to be generated or may be incurred as a result of the Visionix Transaction.

The Unaudited Pro Forma Financial Information has been compiled in accordance with the Annex 20 to the Delegated Regulation 2019/980, and the accounting policies applied in Revenio’s consolidated financial statements as at and for the year ended December 31, 2025, prepared in accordance with IFRS Accounting Standards and consolidated half year report as at and for the six months ended June 30, 2026, prepared in accordance with IAS 34. The Visionix Transaction has been accounted for with the acquisition method in Revenio’s consolidated financial statements in accordance with IFRS Accounting Standards.



Questions and answers

What is the purpose of Revenio’s Offering?

The objective of the Offering is to fund a portion of the cash payments made by Revenio in connection with the Visionix Transaction by repaying the outstanding Bridge Facility related to the Visionix Transaction, whereby Revenio aims to secure balanced capital structure and sufficient financial flexibility to execute its strategy. The Visionix Transaction is a key element in the execution of Revenio’s strategy and strengthens Revenio’s ability to accelerate growth and value creation through a broader market opportunity, increased scale and synergies arising from the Visionix Transaction.

Who has the right to participate in the Offering?

Shareholders who are registered in Revenio’s shareholders’ register maintained by Euroclear Nordics Ltd on the Record Date will receive one (1) subscription right in the form of a book-entry for each one (1) existing share of the Company owned by the shareholder on the Record Date.

If the Offer Shares are not fully subscribed for pursuant to the primary subscription right, both holders of Subscription Rights and investors who do not hold Subscription Rights may submit orders to subscribe for any such Offer Shares (the “Secondary Subscription Right”).

Have Revenio’s shareholders or other investors committed in advance to subscribe for Offer Shares in the Offering?

William Demant Invest A/S, Caravelle Capital SAS and the other sellers in the Visionix Transaction, have each separately and irrevocably committed to subscribe for on the basis of the Subscription Rights allocated to them, an aggregate amount of approximately 31.4 percent of the Offer Shares offered in the Offering, and to pay the Subscription Price for such Offer Shares (either by itself and/or on behalf of its controlled entity) under certain customary conditions.

Pursuant to the Underwriting Agreement, Nordea has agreed, subject to certain customary terms and conditions, to procure subscribers for any Offer Shares that may remain unsubscribed for in the Offering, excluding the Offer Shares that are covered by the Subscription Commitments, or to subscribe for such Offer Shares itself.

When can I subscribe for shares?

The subscription period will commence on September 28, 2026, at 9:30 a.m. (Finnish time) and end on October 12, 2026, at 4:30 p.m. (Finnish time).

How many Offer Shares can I subscribe for?

Nine (9) Subscription Rights entitle its holder to subscribe for four (4) Offer Shares at the Subscription Price.

If the Offer Shares are not fully subscribed for pursuant to the primary subscription right, both holders of Subscription Rights and investors who do not hold Subscription Rights may submit orders to subscribe for any such Offer Shares.

What is the price of an Offer Share?

The Subscription Price is EUR 6.19 per Offer Share.

How can I sell or buy Subscription Rights?

Public trading of the Subscription Rights on the regulated market of Nasdaq Helsinki is expected to commence on September 28, 2026, at 10:00 a.m. (Finnish time) and it ends on October 6, 2026, at 6:30 p.m. (Finnish time).

Will there be any expenses incurred for the subscription?

Neither the Company nor Nordea, in its capacity as global coordinator only, will charge any commission or fees for the subscription of Offer Shares, and no transfer tax is payable for the subscription of Offer Shares. Account operators,

custodians or securities brokers who execute subscription orders relating to the Subscription Rights may charge a commission in accordance with their own terms of service. Account operators and custodians may also charge a fee for the maintenance of a book entry account and the custody of shares in accordance with their terms of service.

How does the subscription of shares take place in practice?

You will receive detailed instructions on how to submit an order to subscribe for Offer Shares from your investment service provider.

What happens if I don’t use my Subscription Rights?

Any unexercised Subscription Rights will expire without any compensation at the end of the subscription period on October 12, 2026, at 4:30 p.m. (Finnish time).

Questions and answers

Can subscriptions be cancelled?

Any exercise of the Subscription Rights or subscription of the Offer Shares pursuant to the Secondary Subscription Right is irrevocable and may not be modified or cancelled other than as set forth in the terms and conditions of the Offering.

Where the prospectus relating to the Offering is supplemented, investors who have subscribed for the Offer Shares before the supplement is published may have the right to withdraw their subscriptions within three working days after the publication of the supplement. The procedure regarding the withdrawal of the subscriptions would be announced together with any such supplement.



Risk factors

Risks related to the Visionix Transaction

Revenio may not be able to realize some or all of the anticipated benefits of the Visionix Transaction, or it may not be successful in integrating Visionix into its existing business in the manner, or within the timeframe, currently anticipated.

The Unaudited Pro Forma Financial Information included in the Offering Circular may not accurately reflect what Revenio’s business, financial condition and results of operations would have been if Visionix had been part of Revenio during the relevant period, and may not be indicative of Revenio’s future business, financial condition and results of operations.

The Visionix Transaction is subject to a number of risks inherent in acquisitions.

Risks related to Revenio’s business and operating environment

Revenio operates in a competitive market and Revenio may fail to successfully implement its strategy, achieve its financial targets or successfully adapt its strategy in a competitive market, which could have a material adverse effect on Revenio’s business, financial condition and/or results of operations.

Revenio may fail to successfully develop and commercialize new products and technologies or to maintain and enhance its existing portfolio, which could result in the depreciation of capitalized development expenses and have a material adverse effect on Revenio’s competitive position and financial results.

Main part of Revenio’s business is dependent on marketing authorizations, including CE markings and device registrations, for the products and services it offers, and any loss or suspension of such marketing authorization or a longer than expected duration of application processes could have a material adverse effect on Revenio’s business.

Revenio is exposed to macroeconomic and geopolitical developments and other macro level risks and developments that could have a material adverse effect on Revenio.

Revenio may not be able to protect its intellectual property rights, trade secrets and know how, and Revenio may unintentionally infringe on intellectual property rights of third parties, and such breaches may result in legal actions, which could have a material adverse effect on Revenio’s business.

Revenio operates in a highly regulated industry, and changes in legislation or case law relating to the industry may have a material adverse effect on Revenio’s business and financial results, and with operations in multiple jurisdictions, Revenio is subject to a variety of laws and regulations, changes in which could have a material adverse effect on Revenio’s business and financial results.

Revenio’s ability to attract and retain qualified personnel, including key management and specialized employees, is critical to its business, and any failure to do so could have a material adverse effect on Revenio.

Revenio’s expansion into new markets involves several risks, and failure to identify suitable customers, obtain necessary regulatory authorizations and achieve estimated benefits could limit its growth and have a material adverse effect on Revenio.

Revenio is subject to risks related to third party suppliers and supply chains, as well as the global availability and prices of electronic components and other raw materials, and any issues or interruptions related thereto could have a material adverse effect on Revenio’s business and results of operations.

Revenio may lose significant customers or fail to build long lasting relationships with new customers.

Potential product quality defects or disruptions to production and deliveries could have a material adverse effect on Revenio’s business and results of operations.

Difficulties in maintaining and updating IT infrastructure, deficiencies in IT systems, and external cyber attacks related to IT systems, as well as resulting data breaches and other consequences, could have a material adverse effect on Revenio.

Revenio may suffer reputational damage as a result of several adverse events, which could have a material adverse effect on Revenio’s business, financial condition and/or results of operations.

Risk factors

Risks related to Revenio's financial condition and financing

Revenio may not necessarily obtain financing on competitive terms or at all, its liquidity may be adversely affected by the profitability of its business operations and prevailing market conditions, and Revenio may not be able to comply with the covenants and other terms of its financing arrangements.

Fluctuations in foreign exchange and interest rates could have a material adverse effect on Revenio.

Revenio is exposed to credit risks.

Risks related to the Shares

The amount of any dividends paid by the Company in any given financial year is uncertain.

The interests of major shareholders may differ from those of other shareholders.

Future share issues and sales of significant number of Shares may reduce the price of the Shares and the future share issues may dilute the share of ownership of the current shareholders.

Holders of nominee registered Shares cannot necessarily exercise their voting rights.

Risks related to the Subscription Rights and the Offering

A shareholder's ownership will be diluted if the shareholder does not exercise the Subscription Rights, and the Subscription Rights could lose all their value.

The Offering may not be fully subscribed for and the Company may not complete the Offering.

Investors do not have the right to cancel the use of Subscription Rights or subscription of the Offer Shares pursuant to the Secondary Subscription Right or sales and other transfers of Interim Shares.

Should the Offering be cancelled, the Subscription Rights would have no value.

The market price of the Subscription Rights and the Offer Shares could fluctuate considerably and the price of the Offer Shares could fall below the Subscription Price.

Shareholders may not necessarily be able to exercise their subscription rights.



Terms and Conditions of the Offer

Overview of the Offering

On May 12, 2026, the Annual General Meeting of Shareholders of Revenio Group Corporation (“Revenio” or the “Company”) authorized the Board of Directors of the Company to decide on a rights issue of up to 14,600,000 new shares in the Company. In the rights issue, the shareholders of the Company will have a pre emptive right to subscribe for new shares in proportion to their shareholdings in the Company. The Board of Directors of the Company was also authorized to decide upon all other terms and conditions of the share issue.

On September 21, 2026, the Board of Directors of the Company resolved, based on the authorization granted by the Annual General Meeting of Shareholders of the Company, to issue a maximum of 12,929,361 new shares in the Company (the “Offer Shares”) in the offering for consideration pursuant to the pre emptive subscription right of the shareholders (the “Offering”) as set forth in these terms and conditions.

The Company will use the net proceeds received from the Offering for the repayment of the outstanding EUR 80 million bridge to equity facility related to the acquisition of LT International SAS, a parent company of Visionix International group, which was completed

on May 28, 2026 (the “Visionix Transaction”), whereby Revenio aims to secure balanced capital structure and sufficient financial flexibility to execute its strategy. The Visionix Transaction is a key element in the execution of Revenio’s strategy and strengthens Revenio’s ability to accelerate growth and value creation through a broader market opportunity, increased scale and synergies arising from the Visionix Transaction.

As a result of the Offering, the total number of the shares in the Company (the “Shares”) may increase from 29,166,913 Shares to a maximum of 42,096,274 Shares. Assuming that the Offering is fully subscribed, the Offer Shares represent approximately 44.4 percent of the existing outstanding Shares and votes in the Company prior to the Offering, and approximately 30.8 percent of all outstanding Shares and votes in the Company upon completion of the Offering.

Subscription Rights

Shareholders of Revenio registered in the Company’s shareholders’ register maintained by Euroclear Nordics Ltd (“Euroclear Nordics”) on the record date of the Offering on September 23, 2026 (the “Record Date”) will receive one (1) subscription right in the form of a book entry (the “Subscription Right”) for each one (1) existing share of the Company

(the “Existing Shares”) owned on the Record Date. No Subscription Rights will be allocated to the Existing Shares held in treasury by the Company. See also “—Shareholders Resident in Certain Unauthorized Jurisdictions” below.

The Subscription Rights will be registered on the shareholders’ book entry accounts no later than on September 25, 2026, in the book entry system maintained by Euroclear Nordics.

Nine (9) Subscription Rights entitle its holder to subscribe for four (4) Offer Shares at the Subscription Price (as defined below) (the “Primary Subscription Right”). No fractions of Offer Shares will be allotted, and a Subscription Right cannot be exercised partially. If the Offer Shares are not fully subscribed for pursuant to the Primary Subscription Right, both holders of Subscription Rights and investors who do not hold Subscription Rights may submit orders to subscribe for any such Offer Shares (the “Secondary Subscription Right”). Offer Shares remaining unsubscribed under the Primary Subscription Right and the Secondary Subscription Right may be directed for subscription as resolved by the Board of Directors. See also “—Subscription Undertakings and Underwriting” and “—Allocation of Offer Shares Subscribed for without Subscription Rights” below.

The Subscription Rights will be publicly traded on the regulated market of Nasdaq Helsinki Ltd (“Nasdaq Helsinki”) from September 28, 2026, to October 6, 2026.

Upon expiry of the Subscription Period (as defined below), unexercised Subscription Rights will lapse without value and will be removed from the holder’s book entry account without separate notification or compensation. If the Offering is not completed, the Subscription Rights cannot be exercised and will be without value. See also “—Approval of Subscriptions and Publication of the Outcome in the Offering” and “—Other Issues” below.

In order not to lose the value of a Subscription Right, a holder of Subscription Rights must either:

- exercise the Subscription Rights to subscribe for the Offer Shares no later than on October 12, 2026, in accordance with instructions from the subscriber’s account operator, custodian or nominee; or
- sell any unexercised Subscription Rights no later than on the last trading day of the Subscription Rights on October 6, 2026.

The shareholder’s and/or investor’s account operator, custodian or nominee may require that a sell or subscription order be submitted on a specific date prior to the end of trading in the Subscription Rights or the expiry of the Subscription Period. See also “—Subscription Period” and “—Trading in Subscription Rights” below.

If an Existing Share entitling its holder to a Subscription Right has been pledged or is subject to any other restrictions, the Subscription Right may not necessarily be exercisable without the consent of the pledgee or the holder of any other right.

Subscription Undertakings and Underwriting

William Demant Invest A/S (“William Demant”), Caravelle Capital SAS (“Caravelle Capital”) and the other sellers in the Visionix Transaction, have each separately and irrevocably committed to subscribe for on the basis of the Subscription Rights allocated to them, an aggregate amount of approximately 31.4 percent of the Offer Shares offered in the Offering, and to pay the Subscription Price (as defined below) for such Offer Shares (either by itself and/or on behalf of its controlled entity) under certain customary conditions (each separately a “Subscription Commitment” and together, the “Subscription Commitments”).

Nordea Bank Abp (“Nordea”) has entered into an underwriting agreement with the Company

(the “Underwriting Agreement”) pursuant to which it has agreed, subject to certain customary terms and conditions, to procure subscribers for any Offer Shares that may remain unsubscribed for in the Offering, excluding the Offer Shares that are covered by the Subscription Commitments, or to subscribe for such Offer Shares itself (the “Underwriting”).

Subscription Price

The subscription price is EUR 6.19 per Offer Share (the “Subscription Price”).

The Subscription Price is based on the Subscription Undertakings and Underwriting received by the Company and has been determined through negotiations between the Company’s main shareholders, investors, Nordea, in its capacity as sole global coordinator of the Offering (the “Global Coordinator”), and the Company. The Subscription Price includes a customary discount compared to the theoretical ex rights price, based on the closing price of the Company’s share on the regulated market of Nasdaq Helsinki on the last trading day immediately preceding the decision on the Offering. The Subscription Price shall be recorded into the Company’s reserve for invested unrestricted equity.

Record Date

The Record Date of the Offering is September 23, 2026.

Subscription Period

The subscription period will commence on September 28, 2026, at 9:30 a.m. (Finnish time) and end on October 12, 2026, at 4:30 p.m. (Finnish time) (the “Subscription Period”). The Board of Directors of the Company is entitled to extend the Subscription Period. Any extension will be announced by the Company through a stock exchange release no later than on October 12, 2026. The shareholder’s and/or investor’s account operator, custodian or nominee may require that a subscription order be submitted on a specific date prior to the end of trading in the Subscription Rights or the expiry of the Subscription Period. The Board of Directors of the Company is entitled to reject subscription orders received after the expiry of the Subscription Period.

Trading in Subscription Rights

Holders of Subscription Rights may sell their Subscription Rights at any time during the public trading of the Subscription Rights. Public trading of the Subscription Rights on the regulated market of Nasdaq Helsinki commences on September 28, 2026, at 10:00 a.m. (Finnish time) and ends on October 6, 2026, at 6:30 p.m. (Finnish time) (unless the Subscription Period is extended). The price of the Subscription Rights on the regulated market of Nasdaq Helsinki will be determined in market trading. Subscription Rights may be sold or purchased by giving a sell or purchase order to one’s own account operator, custodian or nominee. The shareholder’s and/or investor’s account

operator, custodian or nominee may require that a sell or purchase order be submitted on a specific date prior to the end of trading in the Subscription Rights.

The ISIN code of the Subscription Rights on the regulated market of Nasdaq Helsinki is FI4000614920 and the trading code is “REG1VU0126.”

Subscription for Offer Shares with Subscription Rights (Primary Subscription Right)

Directly Registered Shareholders

A shareholder of the Company may participate in the Offering by subscribing for the Offer Shares by using the Subscription Rights on the shareholder’s book entry account and by paying the Subscription Price. However, this may not apply to shareholders resident in certain Unauthorized Jurisdictions (as defined below). Shareholders may be required to certify that they are not residing in an Unauthorized Jurisdiction in connection with any such subscription. In order to participate in the Offering, a shareholder must give a subscription order in accordance with the instructions provided by the shareholder’s own account operator or custodian.

Holders of Subscription Rights purchased on the regulated market of Nasdaq Helsinki must submit their subscription orders in accordance with the instructions given by their own book entry account operator or custodian.

Nominee registered Shareholders

Shareholders and other investors participating in the Offering, whose Existing Shares or Subscription Rights are nominee registered, must submit their subscription orders in accordance with the instructions given by their custodian bank or, if the holding is registered with more than one custodian, through each custodian bank. Subscription and payment must be made in accordance with instructions from the account management organization of the custodian bank. Banks and other custodians are required to read and comply with the restrictions described in “—Shareholders Resident in Certain Unauthorized Jurisdictions” below. Banks, custodians and other nominees may, in connection with any such subscription, be required to certify that shareholders on whose behalf they are holding Existing Shares or Subscription Rights, are not in an Unauthorized Jurisdiction.

General

Subscriptions must be submitted separately for each book entry account. Incomplete or erroneous subscriptions may be rejected. A subscription order may be rejected if the subscription payment is not made according to these terms and conditions or if such payment is incomplete. However, the Board of Directors of the Company may, to the extent permitted under applicable law, decide to accept a subscription order or payment of the Subscription Price made in a manner

deviating from these terms and conditions. If a subscription is rejected, the Subscription Price paid will be refunded to the subscriber. No interest will be paid on the refunded amount.

Any unexercised Subscription Rights will expire without any compensation at the end of the Subscription Period on October 12, 2026, at 4:30 p.m. (Finnish time).

Payments for the Subscriptions

The Subscription Price of the Offer Shares subscribed for in the Offering must be paid in full in euros upon submission of the subscription order in accordance with the instructions given by the subscriber’s account operator, custodian or nominee.

A subscription will be deemed effected only once the subscription form has been received by the subscriber’s account operator, custodian or nominee, and once the Subscription Price has been paid in full.

Interim Shares

The Offer Shares subscribed for in the Offering will be issued as book entry securities in the book entry system maintained by Euroclear Nordics.

The Offer Shares subscribed for pursuant to the exercise of the Subscription Rights will be recorded on the subscriber’s book entry account as interim shares representing the Offer Shares

(the “Interim Shares”) after the subscription has been effected.

Should the Offering be cancelled, the Subscription Price will be refunded to the holders of the Interim Shares. No interest will be paid on the refunded amount. See also “—Approval of Subscriptions and Publication of the Outcome in the Offering,” “—Withdrawal of Subscriptions in Certain Circumstances” and “— Other Issues” below.

The Interim Shares will be combined with the Existing Shares of the Company (ISIN code FI0009010912, trading code “REG1V”) after the Offer Shares have been registered with the trade register maintained by the Finnish Patent and Registration Office (the “Trade Register”). The combination is expected to occur on or about October 19, 2026.

Trading with Interim Shares

The Interim Shares are freely transferable and trading with the Interim Shares on the regulated market of Nasdaq Helsinki, as a separate class of securities, is expected to take place during the period from and including September 29, 2026, up to and including October 16, 2026, under the trading code “REG1VN0126.” The ISIN code of the Interim Shares is FI4000614938.

Subscription for Offer Shares without Subscription Rights (Secondary Subscription Right)

Subscription for the Offer Shares without Subscription Rights shall be effected by a shareholder and/or other investor by submitting a subscription order and simultaneously paying the Subscription Price in accordance with the instructions provided by their book entry account operator, custodian, or in case of nominee registered holders, by the nominee. It may not be possible to provide a subscription order on the basis of the Secondary Subscription Right via an equity savings account (the Act on Equity Saving Account, 680/2019) through certain account operators. In such case, shareholders should provide the secondary subscription order via another book entry account than the equity savings account.

The subscription order and payment must be received by the shareholder’s and/or investor’s account operator, custodian or nominee on October 12, 2026, at the latest, or on such earlier date as specified in the instructions given by the book entry account operator, custodian or nominee.

If several subscription orders are submitted in relation to a single book entry account, the orders will be considered as one order per book entry account.

The Offer Shares subscribed and allocated without Subscription Rights will be recorded on the subscriber’s book entry account as Shares on or about October 19, 2026.

Approval of Subscriptions and Publication of the Outcome in the Offering

The Board of Directors of the Company will approve subscriptions pursuant to the Subscription Rights made in accordance with these terms and conditions of the Offering and applicable laws and regulations on or about October 15, 2026. In addition, the Board of Directors of the Company will, in accordance with the allocation principles set out below in “—Allocation of Offer Shares Subscribed for without Subscription Rights,” approve subscriptions without Subscription Rights made in accordance with these terms and conditions of the Offering and applicable laws and regulations. The Board of Directors of the Company may decide not to approve the subscriptions, including the subscriptions made with Subscription Rights, and not to carry out the Offering, if the Board of Directors of the Company concludes that carrying out the Offering is not in the Company’s interest. In such event, the Subscription Price will be refunded to the holders of Interim Shares and the Subscription Price paid for Offer Shares subscribed without Subscription Rights will be refunded to persons that have submitted subscription orders for such Offer Shares. In the event the Offering is cancelled, the Subscription Rights cannot be exercised and have no value.

Revenio will publish the preliminary results of the Offering in a stock exchange release on or about October 13, 2026.

Revenio will publish the final results of the Offering in a stock exchange release on or about October 15, 2026.

No separate confirmation will be sent in respect of the approval of subscriptions made on the basis of Subscription Rights. In respect of approved subscriptions made without Subscription Rights, the investor’s account operator, custodian or nominee may decide to send a separate confirmation notice following the Offering.

Allocation of Offer Shares Subscribed for Without Subscription Rights

If all the Offer Shares have not been subscribed for pursuant to the exercise of the Subscription Rights, the Board of Directors of the Company will determine the allocation of Offer Shares subscribed for without Subscription Rights as follows:

- first, to those who have also subscribed for Offer Shares pursuant to Primary Subscription Rights. If the Offering is oversubscribed by such subscribers, the allocation among such subscribers shall be determined on a book entry account basis in proportion to the number of Subscription Rights exercised for the subscription of Offer Shares and, where this is not possible, by drawing of lots;

- second, to those who have subscribed for Offer Shares without Subscription Rights pursuant to Secondary Subscription Rights only and, if the Offering is oversubscribed by such subscribers, the allocation among such subscribers shall be determined on a book entry account basis in proportion to the number of Offer Shares which such subscribers have subscribed for and, where this is not possible, by drawing of lots; and
- third, to subscribers procured by Nordea, or, when such subscribers have not been procured, to Nordea in accordance with, and subject to, the terms and conditions of the Underwriting Agreement. The subscription period with respect to Nordea and/or to subscribers procured by it expires on October 15, 2026.

If the allocation of Offer Shares subscribed for without Subscription Rights does not correspond to the amount of Offer Shares indicated in the subscription order, the Subscription Price paid for non allocated Offer Shares will be refunded to the subscriber starting from on or about October 19, 2026. No interest will be paid on the refunded amount.

Withdrawal of Subscriptions in Certain Circumstances

Any exercise of the Subscription Rights or subscription of the Offer Shares pursuant to the Secondary Subscription Right is irrevocable and may not be modified or cancelled other than as set forth below.

Where the Finnish language prospectus relating to the Offering (the “Finnish Prospectus”) is supplemented in accordance with the Prospectus Regulation due to a significant new factor, material mistake or material inaccuracy, which may affect the assessment of the Offer Shares or the Interim Shares, investors who have subscribed for the Offer Shares before the supplement is published shall have the right to withdraw their subscriptions within three working days after the publication of the supplement. The withdrawal right is further conditional on that the significant new factor, material mistake or material inaccuracy referred above has emerged or was noted prior to the end of the Subscription Period or the delivery on the book entry account of the subscriber of the Offer Shares or the Interim Shares which are subject to the withdrawal, whichever occurs earlier.

The procedure regarding the withdrawal of the subscriptions will be announced together with any such supplement to the Finnish Prospectus through a stock exchange release. Any withdrawal of a subscription must relate to the entire subscription of the investor. The withdrawal must be made in writing at the account operator, custodian or nominee in which the subscription order was given.

After the end of the withdrawal period, the right of withdrawal will lapse. Where a subscription is withdrawn, the Subscription Price paid will be returned to the subscriber as soon as possible, within approximately five working days from serving the subscription place with the withdrawal notice. No interest will be paid on the funds returned. If the holder of a Subscription Right or an Interim Share has sold or otherwise transferred the Subscription Right or the Interim Share, such sale or transfer cannot be withdrawn.

Shareholders Resident in Certain Unauthorized Jurisdictions

The granting of Subscription Rights to shareholders resident in countries other than Finland and the issuance of the Offer Shares through exercise of Subscription Rights to persons resident in countries other than Finland may be affected by securities legislation in such countries.

Consequently, subject to certain exceptions, shareholders whose Existing Shares are directly registered on a securities account and whose registered address is in the United States, the United Kingdom, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa or any other jurisdiction in which participation in the Offering would not be permissible (the “Unauthorized Jurisdictions”), may not receive any Subscription Rights and may not be allowed to subscribe for the Offer Shares. In Finland,

each such shareholder, registered in the Company’s shareholders’ register, acting through banks, nominees, custodians or other financial intermediaries through which its Existing Shares are held, may consider selling any and all Subscription Rights held for its benefit, to the extent permitted under their arrangements and applicable law and receive proceeds of sale (less deduction of costs) on their account.

Trading in Offer Shares

Trading in the Offer Shares on the regulated market of Nasdaq Helsinki is expected to commence on or about October 19, 2026.

Shareholder Rights

The Offer Shares will entitle their holders to possible dividend and other distribution of funds, if any, and to other shareholder rights in the Company after the Offer Shares have been registered with the Trade Register, on or about October 16, 2026 and in the Company’s shareholder register maintained by Euroclear Nordics on or about October 19, 2026. Each Offer Share entitles its holder to one vote at the General Meeting of Shareholders of the Company.

Costs and Expenses

Neither the Company nor Nordea, in its capacity as Global Coordinator only, will charge any commission or fees for the subscription of Offer Shares, and no transfer tax is payable for the subscription of Offer Shares. Account operators,

custodians or securities brokers who execute subscription orders relating to the Subscription Rights may charge a commission in accordance with their own terms of service. Account operators and custodians may also charge a fee for the maintenance of a book entry account and the custody of shares in accordance with their terms of service.

Applicable Law and Dispute Resolution

The Offering shall be governed by the laws of Finland. Any disputes arising in connection with the Offering shall be settled by the court of competent jurisdiction in Finland.

In case of any discrepancies between the original Finnish language version and the English language translation of these terms and conditions, the Finnish language version shall prevail.

Other Issues

Documents referred to in Chapter 5, Section 21 of the Finnish Companies Act (624/2006, as amended) are available for review at the website of Revenio at www.reveniogroup.fi/investors/rights_offering_2026 and at the website of Nordea at www.nordea.com/fi/Revenio.

Other issues and practical matters relating to the Offering will be resolved by the Board of Directors of the Company.

Nordea is acting as the Global Coordinator in respect of the Offering (i.e., assisting the Company with certain administrative services concerning the Offering). The fact that Nordea is acting as the Global Coordinator does not, in itself, mean that Nordea regards the subscriber as a customer of Nordea. For the purposes of the Offering, a subscriber is regarded as a customer of Nordea only if Nordea has provided advice to the subscriber regarding the Offering or has otherwise contacted the subscriber individually regarding the Offering, or if the subscriber has an existing customer relationship with the bank. As a consequence of Nordea not regarding the subscriber as a customer in respect of the Offering, the investor protection rules set forth in the Finnish Investment Service Act (747/2012, as amended) will not apply to the Offering. This means, among other things, that neither customer categorization nor a suitability assessment will take place with respect to the Offering. Accordingly, the subscriber is personally responsible for ensuring that he or she possesses sufficient experience and knowledge to understand the risks associated with the Offering.

Subscribers in the Offering will provide personal data to Nordea. Personal data provided to Nordea will be processed in data systems to the extent required to provide services and administer matters in Nordea. Personal data obtained from a party other than the customer to whom the processing relates may also be processed. Personal data may also be processed

in data systems at companies and organizations with which Nordea cooperates. Information regarding the processing of personal data is provided by Nordea's branch offices, which also accept requests for correction of personal data. Information regarding addresses may be obtained by Nordea through automatic data runs at Euroclear Nordics. By subscribing for the Offer Shares in the Offering, the subscriber authorizes their account operator to disclose necessary personal data, the number of their book entry account and the details of the subscription to the parties involved in the processing of the subscription order or the execution of the assignment to allocate and settle the Offer Shares.

www.reveniogroup.fi/investors/
[rights_offering_2026](http://www.reveniogroup.fi/investors/)

REVENIO

www.reveniogroup.fi
ir@revenio.fi

